Development of Highly Selective Kv1.3-Blocking Peptides Based on the Sea Anemone Peptide ShK
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
ShK, from the sea anemone Stichodactyla helianthus, is a 35-residue disulfide-rich peptide that blocks the voltage-gated potassium channel Kv1.3 at ca. 10 pM and the related channel Kv1.1 at ca. 16 pM. We developed an analog of this peptide, ShK-186, which is currently in Phase 1b-2a clinical trials for the treatment of autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. While ShK-186 displays a >100-fold improvement in selectivity for Kv1.3 over Kv1.1 compared with ShK, there is considerable interest in developing peptides with an even greater selectivity ratio. In this report, we describe several variants of ShK that incorporate p-phophono-phenylalanine at the N-terminus coupled with internal substitutions at Gln16 and Met21. In addition, we also explored the combinatorial effects of these internal substitutions with an alanine extension at the C-terminus. Their selectivity was determined by patch-clamp electrophysiology on Kv1.3 and Kv1.1 channels stably expressed in mouse fibroblasts. The peptides with an alanine extension blocked Kv1.3 at low pM concentrations and exhibited up to 2250-fold selectivity for Kv1.3 over Kv1.1. Analogs that incorporates p-phosphono-phenylalanine at the N-terminus blocked Kv1.3 with IC50s in the low pM range and did not affect Kv1.1 at concentrations up to 100 nM, displaying a selectivity enhancement of >10,000-fold for Kv1.3 over Kv1.1. Other potentially important Kv channels such as Kv1.4 and Kv1.6 were only partially blocked at 100 nM concentrations of each of the ShK analogs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The IC50 of ShK-223 for Kv1.3 channels is 25 ± 14 pM, > 10,000 times more selective for Kv1.3 channels as compared to neuronal Kv1.1 and Kv1.2 channels [25].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Voltage-gated K+ channels in human T lymphocytes: a role in mitogenesis?
DeCoursey, T. E., Chandy, K. G., Gupta, S., & Cahalan, M. D. (1984) · Nature · doi:10.1038/307465a0 · Cited by 744 · cited 1×
“3 channel was discovered in the early 1980’s by the Chandy and Cahalan labs at the University of California Irvine [19] and the Deutsch lab at the University of Pennsylvania [20].”
BackgroundKv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases
Beeton, C., Wulff, H., Standifer, N. E., Azam, P., Mullen, K. M., Pennington, M. W., Kolski-Andreaco, A., Wei, E., Grino, A., Counts, D. R., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605136103 · Cited by 538
Self-citationThe voltage-gated Kv1.3 K+ channel in effector memory T cells as new target for MS
Wulff, H., Calabresi, P. A., Allie, R., Yun, S., Pennington, M., Beeton, C., & Chandy, K. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16921 · Cited by 422
Self-citationOn the Convergent Evolution of Animal Toxins
Dauplais, M., Lecoq, A., Song, J., Cotton, J., Jamin, N., Gilquin, B., Roumestand, C., Vita, C., de Medeiros, C. C., Rowan, E. G., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4302 · Cited by 336 · cited 2×
“6 Å from the planar aromatic ring of the Tyr23 residue, a juxtaposition that led to the description of this pairing as a functional diad [14].”
BackgroundBeeton, C., Wulff, H., Barbaria, J., Clot-Faybesse, O., Pennington, M., Bernard, D., Cahalan, M. D., Chandy, K. G., & Béraud, E. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241497298 · Cited by 318
Self-citationK channels in T lymphocytes: a patch clamp study using monoclonal antibody adhesion
Matteson, D. R., & Deutsch, C. (1984) · Nature · doi:10.1038/307468a0 · Cited by 314 · cited 1×
“3 channel was discovered in the early 1980’s by the Chandy and Cahalan labs at the University of California Irvine [19] and the Deutsch lab at the University of Pennsylvania [20].”
BackgroundCastañeda, O., Sotolongo, V., Amor, A. M., Stöcklin, R., Anderson, A. J., Harvey, A. L., Engström, Å., Wernstedt, C., & Karlsson, E. (1995) · Toxicon · doi:10.1016/0041-0101(95)00013-c · Cited by 283 · cited 1×
“This 35-residue peptide, ShK toxin, also contained three disulfide bonds but was the first peptide toxin from a sea anemone that blocked K channels [6].”
BackgroundShK-Dap22, a Potent Kv1.3-specific Immunosuppressive Polypeptide
Kalman, K., Pennington, M. W., Lanigan, M. D., Nguyen, A., Rauer, H., Mahnir, V., Paschetto, K., Kem, W. R., Grissmer, S., Gutman, G. A., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.49.32697 · Cited by 256 · cited 1×
“3 ever described, with an IC50 by patch-clamp of 10 pM [15] and equilibrium binding to Kv1.”
BackgroundSelf-citationBeeton, C., Pennington, M. W., Wulff, H., Singh, S., Nugent, D., Crossley, G., Khaytin, I., Calabresi, P. A., Chen, C.-Y., Gutman, G. A., et al. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.008193 · Cited by 249 · cited 2×
“Other non-hydrolysable analogs of the N-terminal pTyr, such as para phosphonphenylalanine (Ppa), have also been prepared, with and without substitutions of Met21 (ShK-190) with the nonoxidizable Nle residue (ShK-192) [28,32].”
BackgroundSelf-citationSea Anemone (Cnidaria, Anthozoa, Actiniaria) Toxins: An Overview
Frazão, B., Vasconcelos, V., & Antunes, A. (2012) · Marine Drugs · doi:10.3390/md10081812 · Cited by 223
Research works printed but not linked: 1
- Pennington M.W. Kem W.R. Karlsson E. Sea anemone potassium channel toxins Guidebook to Protein Toxins and Their Use in Cell Biology Montecucco C.A.R. Oxford University Press Oxford, UK 1997 159 161
Cited by
Baell, J. B. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b00947 · Cited by 539
Blunt, J. W., Copp, B. R., Keyzers, R. A., Munro, M. H. G., & Prinsep, M. R. (2017) · Natural Product Reports · doi:10.1039/c6np00124f · Cited by 465
Rangaraju, S., Dammer, E. B., Raza, S. A., Rathakrishnan, P., Xiao, H., Gao, T., Duong, D. M., Pennington, M. W., Lah, J. J., Seyfried, N. T., et al. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0254-8 · Cited by 430
“ShK-223 peptide was synthesized and folded as previously described [25].”
MethodSelf-citationSea Anemones: Quiet Achievers in the Field of Peptide Toxins
Prentis, P. J., Pavasovic, A., & Norton, R. S. (2018) · Toxins · doi:10.3390/toxins10010036 · Cited by 131
Self-citationCyclic Peptides in Pipeline: What Future for These Great Molecules?
Costa, L., Sousa, E., & Fernandes, C. (2023) · Pharmaceuticals · doi:10.3390/ph16070996 · Cited by 101
Pérez-Verdaguer, M., Capera, J., Serrano‐Novillo, C., Estadella, I., Sastre, D., & Felipe, A. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1112792 · Cited by 113
“Demonstrated proof-of-concept for psoriasis[42,158] Peptide (anemone toxin) BgK Kv1.”
BackgroundThe secret life of ion channels: Kv1.3 potassium channels and proliferation
Pérez-García, M. T., Cidad, P., & López‐López, J. R. (2017) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00136.2017 · Cited by 114
“Extensive work has focused on the development of more stable and specific Shk analogous for the treatment of autoimmune diseases (13, 29, 130, 156).”
BackgroundFriends or Foes? Emerging Impacts of Biological Toxins
Clark, G. C., Casewell, N. R., Elliott, C. T., Harvey, A. L., Jamieson, A. G., Strong, P. N., & Turner, A. D. (2019) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.12.004 · Cited by 75
Tanner, M. R., Tajhya, R. B., Huq, R., Gehrmann, E. J., Rodarte, K. E., Atik, M., Norton, R. S., Pennington, M. W., & Beeton, C. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.03.014 · Cited by 83
Self-citationRangaraju, S., Raza, S. A., Pennati, A., Deng, Q., Dammer, E. B., Duong, D., Pennington, M. W., Tansey, M. G., Lah, J. J., Betarbet, R., et al. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0906-6 · Cited by 75
Self-citationThe voltage-gated potassium channel KV1.3 as a therapeutic target for venom-derived peptides
Tajti, G., Wai, D. C. C., Panyi, G., & Norton, R. S. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114146 · Cited by 65
Self-citationThe Kunitz-Type Protein ShPI-1 Inhibits Serine Proteases and Voltage-Gated Potassium Channels
García‐Fernández, R., Peigneur, S., Pons, T., Álvarez, C., González, L., Chávez, M. D. C. M., & Tytgat, J. (2016) · Toxins · doi:10.3390/toxins8040110 · Cited by 57
Enhancing the therapeutic potential of peptide toxins
Norton, R. S. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1317243 · Cited by 56
“3 over all other channels [10,15,62] and are being developed for the treatment of autoimmune diseases.”
BackgroundSelf-citationNguyen, H. M., di Lucente, J., Chen, Y., Cui, Y., Ibrahim, R. H., Pennington, M. W., Jin, L., Maezawa, I., & Wulff, H. (2020) · Glia · doi:10.1002/glia.23847 · Cited by 54
Self-citationMurray, J. K., Qian, Y., Liu, B., Elliott, R., Aral, J., Park, C., Zhang, X., Stenkilsson, M., Salyers, K. L., Rose, M. J., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00495 · Cited by 51
Liao, Q., Feng, Y., Yang, B., & Lee, S. M. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.08.011 · Cited by 50
Phosphonopeptides containing free phosphonic groups: recent advances
Kafarski, P. K. (2020) · RSC Advances · doi:10.1039/d0ra04655h · Cited by 48
Harnessing the knowledge of animal toxins to generate drugs
Zambelli, V. O., Pasqualoto, K. F. M., Picolo, G., Chudzinski-Tavassi, A. M., & Cury, Y. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.009 · Cited by 47
Chen, X., Feng, Y., Quinn, R. J., Pountney, D. L., Richardson, D. R., Mellick, G. D., & Ma, L. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000743 · Cited by 45
APETx4, a Novel Sea Anemone Toxin and a Modulator of the Cancer-Relevant Potassium Channel KV10.1
Moreels, L., Peigneur, S., Galan, D. T., Pauw, E. D., Béress, L., Waelkens, E., Pardo, L. A., Quinton, L., & Tytgat, J. (2017) · Marine Drugs · doi:10.3390/md15090287 · Cited by 44
“3 was developed [34] and has currently completed Phase I clinical trials for the treatment of autoimmune diseases [35,36].”
BackgroundVeytia‐Bucheli, J. I., Jiménez-Vargas, J. M., Melchy-Pérez, E., Sandoval-Hernández, M. A., Possani, L. D., & Rosenstein, Y. (2018) · Cell Communication and Signaling · doi:10.1186/s12964-018-0257-7 · Cited by 34
“3 blockers such as Vm24 or other second-generation blockers derived from ShK toxin that have been recently developed [76].”
Wang, Y., Zhu, D., Ortiz-Velez, L., Perry, J. L., Pennington, M. W., Hyser, J. M., Britton, R. A., & Beeton, C. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2211977120 · Cited by 32
Self-citationVenom-derived peptides inhibiting Kir channels: Past, present, and future
Doupnik, C. A. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.07.011 · Cited by 30
“3 channels with high selectivity and picomolar affinity (Pennington et al., 2015).”
BackgroundYe, F., Hu, Y., Yu, W., Xie, Z., Hu, J., Cao, Z., Li, W., & Wu, Y. (2016) · Toxins · doi:10.3390/toxins8040115 · Cited by 27
Chandy, K. G., Sanches, K., & Norton, R. S. (2023) · Channels · doi:10.1080/19336950.2023.2253104 · Cited by 28
“3 with much higher potency than HmK (ShK IC50 11 pM [76,101], HmK IC50 3 nM [102]).”
BackgroundSelf-citationSunanda, P., Krishnarjuna, B., Peigneur, S., Mitchell, M. L., Estrada, R., Villegas‐Moreno, J., Pennington, M. W., Tytgat, J., & Norton, R. S. (2018) · Peptide Science · doi:10.1002/pep2.24073 · Cited by 26
Self-citationProteomic Analysis of the Venom of Jellyfishes Rhopilema esculentum and Sanderia malayensis
Leung, T. C. N., Qu, Z., Nong, W., Hui, J. H. L., & Ngai, S. M. (2020) · Marine Drugs · doi:10.3390/md18120655 · Cited by 24
Paracelsus’ legacy in the faunal realm: Drugs deriving from animal toxins
Fischer, T., & Riedl, R. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.10.003 · Cited by 24
Hemajha, L., Singh, S., Biji, C. A., Balde, A., Benjakul, S., & Nazeer, R. A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113130 · Cited by 24
Krishnarjuna, B., Sunanda, P., Villegas‐Moreno, J., Csóti, A., Morales, R. A. V., Wai, D. C. C., Panyi, G., Prentis, P. J., & Norton, R. S. (2020) · Journal of Structural Biology · doi:10.1016/j.jsb.2020.107692 · Cited by 20
Self-citationBorowski, R. G. V., Macêdo, A. J., & Gnoatto, S. C. B. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.11.008 · Cited by 22
“Peptides are the source of many bioactive compounds with distinct activities, such as immunomodulation (Faruqi, 2013; Sanchez-Margalet et al., 2003; Pennington et al., 2015; Pasikowski et al., 2011), antitumor (Bajou et al., 2014; Chernysh et al., 2002; Martinez-Hoyer et al., 2015), anticancer…”
BackgroundAshwood, L. M., Elnahriry, K. A., Stewart, Z. K., Shafee, T. M. A., Naseem, M. U., Szanto, T. G., van der Burg, C. A., Smith, H. L., Surm, J. M., Undheim, E. A. B., et al. (2023) · BMC Biology · doi:10.1186/s12915-023-01617-y · Cited by 21
Self-citationGuo, Q., Fu, J., Yuan, L., Liao, Y., Li, M., Li, X., Yi, B., Zhang, J., & Gao, B. (2024) · Scientific Reports · doi:10.1038/s41598-024-58402-2 · Cited by 19
Nicolazzo, J. A., Pan, Y., Stefano, I. D., Choy, K. H. C., Reddiar, S. B., Low, Y. L., Wai, D. C. C., Norton, R. S., & Jin, L. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.11.003 · Cited by 19
Self-citationGerdol, M., Cervelli, M., Mariottini, P., Oliverio, M., Dutertre, S., & Modica, M. V. (2019) · Toxins · doi:10.3390/toxins11020106 · Cited by 19
Discovery of novel peptide neurotoxins from sea anemone species
Fu, J., Liao, Y., Jin, A., & Gao, B. (2021) · Frontiers in Bioscience-Landmark · doi:10.52586/5022 · Cited by 19
Optimization of Pichia pastoris Expression System for High-Level Production of Margatoxin
Naseem, M. U., Tajti, G., Gáspár, A., Szanto, T. G., Borrego, J., & Panyi, G. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.733610 · Cited by 19
“3 that is under clinical trials for the treatment of multiple autoimmune disorders (Pennington et al., 2015; Tarcha et al., 2017; Tajti et al., 2020; Wang et al., 2020).”
BackgroundNaseem, M. U., Carcamo-Noriega, E. N., Beltrán-Vidal, J., Borrego, J., Szanto, T. G., Zamudio, F. Z., Delgado-Prudencio, G., Possani, L. D., & Panyi, G. (2022) · The Journal of General Physiology · doi:10.1085/jgp.202213146 · Cited by 17
Nematocyst types and venom effects of Aurelia aurita and Velella velella from the Mediterranean Sea
Killi, N., Bonello, G., Mariottini, G. L., Pardini, P., Pozzolini, M., & Cengiz, S. (2019) · Toxicon · doi:10.1016/j.toxicon.2019.12.155 · Cited by 15
Smallwood, T. B., Navarro, S., Cristofori‐Armstrong, B., Watkins, T. S., Tungatt, K., Ryan, R. Y. M., Haigh, O. L., Lutzky, V. P., Mulvenna, J. P., Rosengren, K. J., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100834 · Cited by 15
Zidar, N., Žula, A., Tomašič, T., Rogers, M., Kirby, R. W., Tytgat, J., Peigneur, S., Kikelj, D., Ilaš, J., & Mašič, L. P. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.015 · Cited by 14
Hoepner, C. M., Stewart, Z. K., Qiao, R., Fobert, E. K., Prentis, P. J., Colella, A. D., Chataway, T., da Silva, K. B., & Abbott, C. A. (2024) · Toxins · doi:10.3390/toxins16020085 · Cited by 14
Hu, H., Mawlawi, S. E., Zhao, T., Deuis, J. R., Jami, S., Vetter, I., Lewis, R. J., & Cardoso, F. C. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.742457 · Cited by 13
“…trials such as chlorotoxin derivates for tumour painting in intraoperative visualization (Patil et al., 2019), and the ShK-186 analogue derived from the venom peptide ShK from sea anemone for the treatment of autoimmune diseases such as psoriatic arthritis and lupus (Pennington et al., 2015).”
BackgroundElnahriry, K. A., Wai, D. C. C., Ashwood, L. M., Naseem, M. U., Szanto, T. G., Guo, S., Panyi, G., Prentis, P. J., & Norton, R. S. (2023) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2023.140952 · Cited by 12
Self-citationReddiar, S. B., Jin, L., Wai, D. C. C., Csóti, A., Panyi, G., Norton, R. S., & Nicolazzo, J. A. (2021) · Toxicon · doi:10.1016/j.toxicon.2021.03.002 · Cited by 12
Self-citationCsóti, A., Meza, R. D. C. N., Bogár, F., Tajti, G., Szanto, T. G., Varga, Z., Gurrola, G. B., Tóth, G. K., Possani, L. D., & Panyi, G. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115023 · Cited by 11
Conformational exchange in the potassium channel blocker ShK
Iwakawa, N., Baxter, N. J., Wai, D. C. C., Fowler, N. J., Morales, R. A. V., Sugase, K., Norton, R. S., & Williamson, M. P. (2019) · Scientific Reports · doi:10.1038/s41598-019-55806-3 · Cited by 12
Self-citationSanches, K., Prypoten, V., Chandy, K. G., Chalmers, D. K., & Norton, R. S. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c01237 · Cited by 11
Self-citationCarden, H., Harper, K. L., Mottram, T. J., Manners, O., Allott, K. L., Dallas, M. L., Hughes, D. J., Lippiat, J. D., Mankouri, J., & Whitehouse, A. (2024) · Science Signaling · doi:10.1126/scisignal.adg4124 · Cited by 9
Sanches, K., Ashwood, L. M., Olushola‐Siedoks, A. A., Wai, D. C. C., Rahman, A., Shakeel, K., Naseem, M. U., Panyi, G., Prentis, P. J., & Norton, R. S. (2023) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26594 · Cited by 6
Self-citationKady, M. R., Elston, R. N., Snyder, L. J., Fleischman, J. D., Brandt, M. J., Zhu, D., Britton, R. A., & Beeton, C. (2025) · Microbial Cell Factories · doi:10.1186/s12934-025-02800-2 · Cited by 5
“While both IbTX and ShK-235 are disulfide-rich peptides ~ 4 kDa in size, their conformational folds are otherwise dissimilar [21, 22].”
Self-citationKazemi‐Lomedasht, F., Eftekhari, Z., Chiani, M., Ramezanpour, S., & Montazeri, A. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115817 · Cited by 5
Methotrexate, a small molecular scaffold targeting Kv1.3 channel extracellular pore region
Xie, Z., Zhao, Y., Yang, W., Li, W., Wu, Y., & Chen, Z. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.08.050 · Cited by 5
Lee, R. D., Chen, Y., Singh, L., Nguyen, H. M., & Wulff, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1190476 · Cited by 5
Obiajulu, C., Nguyen, D., Bui, K. H. N., Tran, T. H., Vu, A., Ngo, C., Slowinski, I. A., Miyazawa, K., & Slowinska, K. (2025) · Cosmetics · doi:10.3390/cosmetics12030086 · Cited by 4
Liu, Y., Zhang, J., Wang, R., Wu, Y., Wang, W., Xin, X., Du, M., Cao, Y., & Zhang, H. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.01.014 · Cited by 3
Zakariya, M., Lincoln, O. J., D’Ambra, I., & Lauritano, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136109 · Cited by 2
“1 is reported to be >100-fold greater than ShK [45,46].”
Kv1.3 Channel inhibition by nanoformulated MeuKTx as a therapeutic strategy in breast cancer
Kazemi‐Lomedasht, F., Eftekhari, Z., & Safarpour, H. (2026) · Scientific Reports · doi:10.1038/s41598-026-47073-w · Cited by 2
Wang, X., Zhang, S., Zhu, Y.-D., Zhang, Z., Sun, M.-Y., Cheng, J.-W., Xiao, Q., Li, G., & Tao, J. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.90889 · Cited by 2
Ion Channels as Therapeutic Drug Targets
García, M. L., & Kaczorowski, G. J. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc255 · Cited by 2
Kumari, R., Bowen, C. A., Srivastava, U., Brandelli, A. D., Kumar, P., Kour, D., Malepati, S., Jang, W. E., Bromwich, M., Zeng, H., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.25.696456 · Cited by 2
Therapeutic Targeting of Potassium Channels
Gamper, N. L., Huang, D., Qi, J., Dong, L., & Zhang, H. (2024) · Springer eBooks · doi:10.1007/978-3-031-52197-3_5 · Cited by 1
Baena-Nuevo, M., Vera‐Zambrano, A., Martínez‐Laperche, C., Buño, I., Muñoz‐Calleja, C., Valenzuela, C., Zapata, J. M., & Pérez-Chacón, G. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178281 · Cited by 1
Wang, Y., Hurley, A. E., Giorgi, M. D., Tanner, M. R., Hu, R.-C., Pennington, M. W., Lagor, W. R., & Beeton, C. (2023) · PLoS ONE · doi:10.1371/journal.pone.0283996 · Cited by 2
Self-citationIon Channel Tools and Therapeutics from Venoms and Toxins
Trim, C. M., Leffler, A. E., Samanani, Z., & Trim, S. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-52197-3_15 · Cited by 1
Kv1.3 Selective Peptides Based Upon N-Terminal Extension and Internal Substitutions of ShK Toxin
Estrada, R., Huq, R., Tajhya, R. B., Chauhan, S. S., Beeton, C., & Pennington, M. W. (2015) · American Peptide Symposium (APS) · doi:10.17952/24aps.2015.238
Self-citationDuque Valderrutén, K. (2016) · Biblioteca Digital - Universidad Icesi
Borowski, R. G. V. (2019) · theses.fr (ABES) · doi:10.70675/1a5d363az5927z498az85eez76eead6906b8 · Cited by 1
Zhang, D., Cao, S., He, S., Mao, S., Luo, S., & Ding, L. (2026) · Medicinal Research Reviews · doi:10.1002/med.70067
“It is evident that this combinatorial strategy plays a crucial role in optimizing drugs; however, it is essential to identify key interactions and critical residues to make future optimization more targeted [25].”
Kim, J., Kim, D., Lee, N., Oh, H., An, H., Jo, Y., Won, H., An, S. S. A., & Yum, S. (2026) · Marine Drugs · doi:10.3390/md24110407
Metadata
- Authors
- Pennington, M., Chang, S., Chauhan, S., Huq, R., Tajhya, R., Chhabra, S., Norton, R., & Beeton, C.
- Affiliations
- Peptides International (United States) (US)
- Monash University (AU)
- Baylor College of Medicine (US)
- Corresponding author
- Pennington, Michael
- ORCID
- Venue
- Marine Drugs
- Publisher
- MDPI AG
- Published
- 2015-01-16
- Volume
- 13
- Issue
- 1
- Pages
- 529-542
- ISSN
- 1660-3397 (ISSN-L)
- PMC
- PMC4306950
- OpenAlex
- W2008077937
- Cited by
- 70
- References
- 38
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 6 · 2023: 10 · 2022: 3 · 2021: 9 · 2020: 7 · 2019: 6 · 2018: 5 · 2017: 9 · 2016: 4 · 2015: 3
- FWCI
- 3.33
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Marine Drugs (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Monash University Research Portal (Monash University) (submittedVersion, other-oa)
- Funders
- NIH (NS073712)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Keywords
- Kv1.3 potassium channel, Kv1.1, voltage-gated potassium channels, disulfide-rich peptides, peptide analogues, channel selectivity, Kv1.4, Kv1.6, autoimmune disease therapy, Stichodactyla helianthus
- MeSH terms
- Amino Acid Sequence, Animals, Chromatography, High Pressure Liquid, Dose-Response Relationship, Drug, Molecular Sequence Data, Peptides, Sea Anemones, Patch-Clamp Techniques, Inhibitory Concentration 50, Kv1.1 Potassium Channel, Kv1.3 Potassium Channel, Chromatography, Reverse-Phase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.